SEC Form 4 · accession 0001144204-15-061709
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Pollack
Officer — Chief Financial Officer · Director · 10% Owner
Period of report
Dec 10, 2014
Accepted (ET)
Oct 30, 2015 · 6:03 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF2,F3,F1 | $8.00 | May 1, 2013 | A | 190,000 | A | May 1, 2013 | Apr 30, 2023 | Common Stock, par value $0.001 per share | 190,000 | 390,000 | D |
| OptionsF4,F3 | $10.00 | May 1, 2013 | A | 165,000 | A | May 1, 2013 | Apr 30, 2023 | Common Stock, par value $0.001 per share | 165,000 | 555,000 | D |
| OptionsF3 | $15.00 | Aug 1, 2013 | A | 50,000 | A | Aug 1, 2013 | Jul 31, 2023 | Common Stock, par value $0.001 per share | 50,000 | 605,000 | D |
| OptionsF3 | $20.00 | Aug 1, 2013 | A | 50,000 | A | Aug 1, 2013 | Jul 31, 2023 | Common Stock, par value $0.001 per share | 50,000 | 655,000 | D |
| OptionsF3 | $6.00 | Dec 31, 2013 | A | 75,000 | A | Dec 31, 2013 | Dec 30, 2023 | Common Stock, par value $0.001 per share | 75,000 | 730,000 | D |
| OptionsF3,F5 | $5.00 | Jun 15, 2014 | A | 150,000 | A | Jun 15, 2014 | Jun 14, 2024 | Common Stock, par value $0.001 per share | 150,000 | 880,000 | D |
| OptionsF3,F5 | $8.00 | Jun 15, 2014 | A | 200,000 | A | Jun 15, 2014 | Jun 14, 2024 | Common Stock, par value $0.001 per share | 200,000 | 1,080,000 | D |
| OptionsF4,F6 | $7.25 | Oct 27, 2015 | A | 500,000 | A | Oct 27, 2015 | Oct 26, 2025 | Common Stock, par value $0.001 per share | 500,000 | 1,580,000 | D |
Explanation of responses
- F1This Form 4 is a late filing reporting the changes in beneficial ownership of the Reporting Person as of October 29, 2015. This Form 4 was required to be filed within two business days of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. The Reporting Person voluntarily filed a Form 3 on December 6, 2012 and a Form 4 on January 3, 2013. In December 2014, the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 3 been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options.
- F250,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 90,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates.
- F3Cashless options.
- F425,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 90,000 vested on 12/31/13. All expire 10 years after their respective vesting dates.
- F5These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date.
- F6These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.